OnKure Therapeutics, Inc. (OKUR)

OKUR Biotech / Pharma

BiotechSign Signal Grade

F
Signal Grade
11.5/100 composite signal score

Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.

Insider Buying
0
Dilution Risk
62
Clinical Activity
0
Short Interest
30

Pipeline Overview

Therapeutic Focus
Biotech / Pharmasrc

Clinical Trial Activity

0
Clinical Trials
(ClinicalTrials.gov aggregate)
0
PubMed Publications
0
Catalyst Records

ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov

Dilution Risk

HIGH DILUTION RISK
38.4 months
Cash Runway Estimate
62/100
Dilution Score
9,430,959
Outstanding Warrants
70Warrant Risk
35Convertible Risk
92Offering Ability

Dilution score: 62/100 (HIGH), 38.4 months cash

Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score

Short Interest

6.99%
Float Shorted
4.8
Days to Cover
MODERATE
Squeeze Risk
-11.0%
SI Change
DECREASING
Trend
1,223,923
Shares Short

Short interest: 6.99% of float, squeeze risk: MODERATE

FINRA short sale data. FINRA short interest

Recent News & SEC Filings

Headlines from public sources. BiotechSign does not endorse or verify linked content.

Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for OnKure Therapeutics, Inc..

Full OKUR Dashboard Sign Up Free

Primary Sources

This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.